Talaporfin

From WikiProjectMed
Jump to navigation Jump to search
Talaporfin
Talaporfin.png
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
IV
ATC code
  • none
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • N-{[(2S,3S)-7-carboxy-3-(2-carboxyethyl)-12-ethyl-2,8,13,18-tetramethyl-17-vinyl-2,3-dihydroporphyrin-5-yl]acetyl}-L-aspartic acid
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC38H41N5O9
Molar mass711.772 g·mol−1
3D model (JSmol)
  • CCC1=C2C=C3C(=C(C(=N3)C(=C4[C@H]([C@@H](C(=N4)C=C5C(=C(C(=CC(=C1C)N2)N5)C=C)C)C)CCC(=O)O)CC(=O)N[C@@H](CC(=O)O)C(=O)O)C(=O)O)C
  • InChI=1S/C38H41N5O9/c1-7-20-16(3)24-12-26-18(5)22(9-10-32(45)46)35(42-26)23(11-31(44)41-30(37(49)50)15-33(47)48)36-34(38(51)52)19(6)27(43-36)14-29-21(8-2)17(4)25(40-29)13-28(20)39-24/h7,12-14,18,22,30,39,43H,1,8-11,15H2,2-6H3,(H,41,44)(H,45,46)(H,47,48)(H,49,50)(H,51,52)/b24-12-,25-13-,26-12-,27-14-,28-13-,29-14-,35-23-,36-23-/t18-,22-,30-/m0/s1 ☒N
  • Key:VSEIDZLLWQQJGK-WSUYNKMOSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Talaporfin (INN, also known as aspartyl chlorin, mono-L-aspartyl chlorin e6, NPe6, or LS11) is a chlorin based photosensitizer used in photodynamic therapy (PDT).

It absorbs red light at 664-667 nm normally provided by a laser tuned to this wavelength.[1]

It was approved in Japan (in 2004) for PDT of lung cancer and marketed as Laserphyrin.[2]

References

  1. ^ Usuda J, Kato H, Okunaka T, Furukawa K, Tsutsui H, Yamada K, Suga Y, Honda H, Nagatsuka Y, Ohira T, Tsuboi M, Hirano T (June 2006). "Photodynamic therapy (PDT) for lung cancers". Journal of Thoracic Oncology. 1 (5): 489–93. doi:10.1016/S1556-0864(15)31616-6. PMID 17409904.
  2. ^ Usuda J, Kato H, Okunaka T, Furukawa K, Honda H, Suga Y, Hirata T, Ohira T, Tsuboi M, Hirano T (June 2006). "Photodynamic therapy using Laserphyrin for centrally located early stage lung cancer". Journal of Clinical Oncology. 24 (18 suppl): 7229. doi:10.1200/jco.2006.24.18_suppl.7229.

Extracorporeal Photo-Immunotherapy for Circulating Tumor Cells